secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2026-08-25T11:30:33+00:00
Accession:  0001213900-26-093244
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex doses first patient in DReAMzz Phase 2 study of IHL-42X for sleep apnea
--------------------------------------------------------------------------------

- First patient dosed in DReAMzz Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea (OSA).
- All 14 U.S. clinical trial sites have IRB approval; drug product manufactured and patient screening underway.
- Builds on Phase 2 RePOSA results: statistically significant AHI reductions vs placebo, individual reductions up to 83%.
- FDA granted Fast Track designation to IHL-42X program, supporting expedited development and review.
- Study aims to optimize dose selection and inform design of planned Phase 3 development program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026093244/0001213900-26-093244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026093244/ea0303140-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-093244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer